Resilience Signs Multi-Year Strategic Biomanufacturing Partnership with Leading Pharmaceutical Company

National Resilience, (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing. The broad agreement encompasses the potential manufacturing for Biologics, Vaccines, Nucleic Acids, Cell and Gene Therapy modalities. The first product under the agreement will be manufactured at Resilience’s newly acquired site in Cincinnati, Ohio, the company’s global center of excellence for commercial drug product manufacturing.

 Latest Hybrid Natural Language Insights : Expert.ai Announces New Features to Hybrid Natural Language Platform

“The partnership announced today is a major milestone for Resilience”

“The partnership announced today is a major milestone for Resilience,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “We are grateful to have this opportunity to work with our partner to deliver important, life-saving medicines to patients. We understand the trust placed with us to manufacture the medicine with the highest quality, regulatory compliance, and reliability. We are committed to maintaining a responsible manufacturing operation that exceeds the expectations of our partners and enables us to make a meaningful impact on global healthcare.”

Read More NLP News: Lion Announces It Will Explore ChatGPT Related AI & NLP Technologies To Empower Digital Program

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions

NLP AiThority News : NLP Leader Huma.AI Launches Industry’s First Generative AI Platform for Life Sciences

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Resilience Signs Multi-Year Strategic Biomanufacturing Partnership with Leading Pharmaceutical Company appeared first on AiThority.

manufacturing
gene therapy
vaccines
biologics
biopharmaceutical
life sciences
healthcare
ai
medicine
pharmaceutical